SYSTEMATIC REVIEW article
Front. Pediatr.
Sec. Pediatric Immunology
Volume 13 - 2025 | doi: 10.3389/fped.2025.1545788
This article is part of the Research TopicChallenges And Advances In Primary Antibody Deficiencies Diagnosis, Treatment And Follow-upView all articles
Glucocorticoids and immunoglobulin alone or in combination in the treatment of multisystemic inflammatory syndrome in children: a systematic review and network meta-analysis
Provisionally accepted
- 1Shenyang Pharmaceutical University, Shenyang, China
- 2Northern Theater Command General Hospital, Shenyang, Liaoning Province, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Importance/Background: Multisystem Inflammatory Syndrome in Children (MIS-C) has sparked the creation of diverse treatment guidelines by healthcare organizations globally. The initial management strategies for MIS-C differ among these guidelines. In developed nations, intravenous immunoglobulin (IVIG) is frequently advised as the first-line treatment. However, given its high cost and limited availability in numerous countries, there is a pressing need for evidence to validate alternative therapeutic options.Objective: To evaluate the efficacy of glucocorticoids (GCs), IVIG, and combination therapy for the treatment of Children with MIS-C.
Keywords: Intravenous Immunoglobulin, Glucocorticoids, Multisystemic inflammatory syndrome in children, COVID-19, combination therapy
Received: 08 Jan 2025; Accepted: 12 May 2025.
Copyright: © 2025 Lin, Tong, Huang, Liu, Kang, liu, wang, Ren and Yuan. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Junjie Lin, Shenyang Pharmaceutical University, Shenyang, China
Yuan Yuan, Northern Theater Command General Hospital, Shenyang, 110017, Liaoning Province, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.